Lisa Cook sues Trump over firing attempt, emergency hearing set
Viemed Healthcare Inc. (NASDAQ:VMD) Vice President of Sales Jerome Cambre sold 4,880 shares of common stock on August 13, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold in two separate transactions at prices ranging from $7.32 to $7.33, netting a total of $35,737. The healthcare company, currently valued at $270 million, has maintained strong profitability with a 58% gross margin and carries minimal debt, according to InvestingPro data.
Specifically, Cambre sold 1,580 shares at $7.33 and 3,300 shares at $7.32. Following these transactions, Cambre directly owns 84,191 shares of Viemed Healthcare. The stock, currently trading at $6.89, appears undervalued based on InvestingPro’s Fair Value analysis, with analysts setting price targets between $11 and $15.
The sales were disclosed in a Form 4 filing signed by Jesse Bergeron, Attorney-in-Fact, on August 14, 2025. Discover more insights about VMD and access comprehensive analysis with InvestingPro’s detailed research report, one of 1,400+ available for top US stocks.
In other recent news, Viemed Healthcare announced a new share repurchase program, approved by its Board of Directors, to buy back up to 1,976,441 common shares, representing about 5% of the total outstanding shares as of March 31, 2025. This initiative, set to run through June 2026, will be conducted in the open market or through block purchases, adhering to securities laws. CEO Casey Hoyt cited the company’s strong financial results and strategic acquisitions, like the planned purchase of Lehan’s Medical, as part of Viemed’s disciplined capital allocation strategy. Viemed Healthcare also emphasized its robust liquidity position, including an untouched $55 million credit facility, to support these buybacks and growth initiatives.
Additionally, Viemed Healthcare’s shareholders approved key amendments during the Annual General and Special Meeting held on June 5, 2025, in Lafayette, Louisiana. The amendments to the 2024 Long Term Incentive Plan (LTIP) include an increase in the maximum number of common shares available, clarification of vesting conditions in the event of a change in control, and the establishment of a minimum one-year vesting period for all awards. These changes align with the company’s strategic goals to enhance its compensation structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.